China: China's Central Government Unveils Final Policy For Drug And Device Regulatory Reform

Last Updated: 12 October 2017
Article by Katherine Wang

Most Popular Article in China, October 2017

Based on the CFDA's policy proposals published in May 2017, China's central government announced its final policy for drug and device regulatory reform on October 8, 2017 ("Final Policy"). The Final Policy reiterates the importance of creating an innovative-conducive regulatory system and incorporates the CFDA's main proposals to deregulate the conduct of clinical studies, to accelerate drug and device approvals, and to reinforce the responsibility of Marketing Authorization Holders.

In addition, the Final Policy attempts to strike a balance between the potentially conflicting interest of innovative and generic drug manufacturers. For example, the Final Policy modifies certain initiatives concerning the exclusivity entitlement of innovative drugs in the CFDA's draft. Compared with the CFDA's proposals, the Final Policy removes procedural details of the patent linkage system and the specific number of years of regulatory data protection for eligible drugs. The Final Policy seems to have intentionally left these details for further elaboration in the implementing measures to be issued by the CFDA and other related government authorities, e.g., the State IP Office.

Last but not least, the Final Policy introduces a few new initiatives that were not included in the original CFDA's proposals. It announces a pilot program to grant compensatory patent term extensions to selective new drugs under defined conditions. Meanwhile, it also calls for the CFDA's actions to promote early launch of generic drugs, biosimilars, and follow-on drug-device combination products to improve accessibility and reduce the health care burden.

Highlights of the Final Policy include the following:

  1. Deregulating the conduct of clinical studies: The Final Policy upholds the CFDA's proposal to simplify the qualification process for clinical study sites and the ethics committee approval process. According to the Final Policy, companies need to secure the relevant ethics committee approvals before applying for the Clinical Trial Authorization. Nevertheless, the Final Policy neither explicitly sets a time limit for the Clinical Trial Authorization process (a time limit of 60 working days was previously provided in the CFDA's proposals), nor explicitly allows foreign companies to conduct Phase 1 studies in China.
  2. Accelerating the drug and device approval process: The Final Policy upholds the CFDA's proposal for conditional approvals for urgently needed therapies and orphan drugs, as well as market access benefits for new drugs. A rare disease catalogue and a rare disease patient registration system will be set up, and applicants of new products treating rare diseases may be eligible for reduced trials. Innovative drugs and devices funded by China's national R&D research grants will be eligible for priority reviews.
  3. Promoting drug innovation and the growth of generics: The Final Policy re-affirms the CFDA's proposals to establish a patent linkage system and to enhance regulatory data protection. However, the Final Policy removes the procedural details pertaining to both mechanisms. Generic manufacturers are required to notify patent holders of their applications for marketing authorizations in order to allow their timely filing of patent litigation claims. The CFDA/CDE's review of the generic applications does not automatically stay during the patent disputes. China's unique patent linkage system may not be able to sufficiently protect patent holders in its implementation, because the China Orange Book has not been formally announced, and follow-on applicants will not be motivated to voluntarily notify the parent holders.
  4. Strengthening the administration and supervision throughout product life cycles: The Marketing Authorization Holder system will be rolled out nationwide for both drugs and devices, allowing research-focused individuals and organizations to become license holders. However, the Marketing Authorization Holders will be held ultimately responsible for pre-approval and post-approval compliance obligations, as well as for the activities of their contracted research organizations, manufacturers and distributors. The CFDA and local FDAs will continue to ensure GCP, GMP, and GSP compliance through rigorous inspections. The Marketing Authorization Holders also need to register their medical representatives with local FDAs in order to detail physicians.
  5. Enhancing technical review infrastructure: The Final Policy upholds the CFDA's proposal for a multi-disciplinary technical review system and reinforces the CFDA and Center for Drug Evaluation ("CDE") officials' confidentiality undertakings during the technical review process. Technical review conclusions will be made public for transparency and better oversight (except for company confidential information). The Final Policy accepts the CFDA's proposals for allowing CTA applicants' pre-submission consultation meetings with the CDE, but it removes procedural details therefrom. It also declares that the authority for technical reviews concerning Class 2 medical devices will be gradually consolidated by the Center for Medical Device Evaluation.

The Final Policy will likely reshape the competitive dynamics in China's life sciences industry. R&D-based pharmaceutical and medical device manufacturers should carefully study the Final Policy, monitor the follow-on implementation measures to be issued, and analyze their impacts on business operations in China.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions